The company has not filed an annual or quarterly report since its FY2024 20-F, filed May 9, 2025. Its latest SEC filing is a 15-12G from Dec 3, 2025.
20-F for FY2024, filed May 9, 2025
The sections below describe the company as of the FY2024 annual report.
Develops donor-derived immune-cell therapies intended to treat patients with cancers and viral infections.
20-F for FY2024, filed May 9, 2025
Partners fund or partly fund collaborative research and development, while physicians who participate in the company's clinical studies are described as future customers.
20-F for FY2024, filed May 9, 2025
Competes with AdicetBio, Allogene, Autolus, Gamma Delta Therapeutics, In8Bio, Novartis, Gilead, and Bristol Myers Squibb
20-F for FY2024, filed May 9, 2025TC BioPharm is part of a growing number of companies commercially active in the cellular immunotherapy space. Such companies developing…View ↗
Loading...